Psoriasis is a common immune-meditated chronic skin disease often characterized as red, scaly plaques that itch, burn, sting, and bleed easily. Psoriasis afflicts approximately 125 million people worldwide; more than 90% of patients have the mild to moderate form. It is incurable and can only be treated for symptomatic relief. Psoriasis is found in all age groups and often seriously compromises the quality of life of those affected. Current methods of Psoriasis treatment are either inconvenient, show poor remission rates and/or have serious side effects. "It's a cruel disease, for which there is no known cure, one that has ravaged the lives of countless North Americans". "You can't catch it, you inherit it. In fact that's the case in 96 per cent of the people who suffer from psoriasis or eczema", says Dr. D.J. Weiland M.D., CEO and founder of Apollo. Apollo, recognizing the need for improved Psoriasis treatments, has taken a natural plant source and, through rigorous scientific development, produced Reliéva®, our first new medication for the effective treatment of psoriasis, with the distinction of being a homeopathic product. Reliéva® has shown its efficacy and excellent tolerability in a 200 patient, Double Blinded Placebo Controlled Study recently published in the American Journal of Therapeutics (13, 121-126, 2006) "This trial is part of our extensive research program of laboratory studies, clinical trials and product research to develop a matrix of new products and treatments in dermatology for psoriasis, eczema and other dry skin conditions." Double Blind Placebo Controlled Psoriasis Treatment Study The 200 patient double-blind, placebo controlled clinical study published by the American Journal of Therapeutics was designed to evaluate the effectiveness of Reliéva® in the treatment of Psoriasis. This study, which met the "gold standard" for scientific assessment, found Reliéva® steroid free cream provided significant improvement as measured by the Psoriasis Area Severity Index (PASI) as well as Quality of Life Index scores. The study was conducted over a 12 week period by Global Clinical Research Inc., based in Los Angeles (